echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma's stock price fell on suspension of vaccination of two batches of new crown vaccine! The company responded urgently...

    Fosun Pharma's stock price fell on suspension of vaccination of two batches of new crown vaccine! The company responded urgently...

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 24th, the Macao Coordination Center for Coordination of New Coronavirus Infections issued a notice indicating that the Macao Health Bureau has recently received a written notice from Fosun Industrial (Hong Kong) Co.


    Screenshot of Macau SAR government announcement

    Screenshot of the Hong Kong Special Administrative Region Government Announcement

    According to previous reports in Hong Kong media, on February 27, 585,000 doses of the first batch of 1 million doses of Fupbitil vaccine were shipped from Germany to Hong Kong, and the remaining doses were shipped to Hong Kong in early March.


    Renaissance emergency response to A+H shares double diving

    Renaissance emergency response to A+H shares double diving

    Not long after, Fosun Pharma responded to the news that "mRNA new crown vaccine is covered with related defects, Hong Kong and Macao will suspend vaccination today.


    Affected by this news, as of today's close, Fosun Pharma’s A shares fell 5.


    It is understood that the mRNA new crown vaccine BNT162b2 mentioned in this announcement was first developed by Baintech, Germany.


    In January and February of this year, BNT162b2 was approved for emergency use in Hong Kong, China and a special import license from the Health Bureau of Macau, China.


    5 new crown vaccines have been listed in China

    5 new crown vaccines have been listed in China

    According to the previous press conference held by the State Council’s Joint Prevention and Control Mechanism on the safety and effectiveness of the new coronavirus vaccine, there are currently 5 vaccines in my country, namely:

    Inactivated vaccine:

    Sinopharm Zhongsheng Beijing Company's new coronavirus inactivated vaccine was approved for listing with conditions on December 31, 2020;

    Kexing Zhongwei new coronavirus inactivated vaccine was approved for marketing with conditions on February 5, 2021;

    Sinopharm Zhongsheng Wuhan Company's new coronavirus inactivated vaccine was approved for marketing conditionally on February 25, 2021.


    Adenovirus vector vaccine:

    The recombinant new coronavirus vaccine developed by CanSino Bio will be approved for marketing with conditions on February 25, 2021.


    Recombinant protein vaccine:

    The Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongke Co.


    Yesterday, CanSinoBio issued an announcement on the Hong Kong Stock Exchange stating that the inhaled recombinant new coronavirus vaccine (type 5 adenovirus vector) developed in cooperation with the Institute of Bioengineering, Academy of Military Sciences, Academy of Military Sciences of the Chinese People’s Liberation Army obtained NMPA on March 22 Approval for clinical trials of drugs.


    Although there is no direct evidence in the announcement issued by Fosun at midday to indicate whether the safety of this batch of products is at risk, under such fierce competition in the domestic vaccine approval market, whether Fosun Pharma’s voluntary recall will give it a later stage Relevant product research and development will bring uncertainties in China's approval, which remains to be seen.


    Reference: "Fosun Pharma: Vaccines are suspended from use in Hong Kong and Macau and sealed up, and are highly responsible for product safety"

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.